Important Research About EquiOtic™ Probiotic

Research 2018-03-27T13:42:56+00:00

The EquiOtic™ line of immunoprobiotics is the result of vast amounts of research. Much of it independent from BlueGrass Equine Products. Below are sites and papers for you to read and make your own decision. We believe that EquiOtic™ is the best direct fed microbial available today on the market. Read what information is behind our products. Who else would give you this kind of information?

Read Japanese Foal Article

Salmonella Antimicrobial Activity of Selected Strains of Enterolactobacillus
Species Isolated from the Gastrointestinal Tract of the Horse

Open PDF

Read Veterinary Science Article

Evaluation of Host-Specific Lactobacillus Probiotic in Neonatal Foals

Open PDF

Japanese Foal Study
Bacteria-Hind Gut Study
Saccharomyces boulardii Study Abstract
Research on Lreuteri and allergic reactions

L. reuteri studies

Wound recovery increased via l. reuteri
Sustain Youthful Serum Testosterone Levels and Testicular Size in Aging Mice
Mammary Immune studies in Mice

European  Food Safety Authority ruling


  1. Drobogosz WJ. Enhancement of human health with Lactobacillus reuteri a probiotic, immunobiotic and immunoprobiotic. Nutrafoods 2005; 4: 15-28
  2. MitsuokaT.  The Human Gastrointestinal Tract. In: Wood BJ, editor. TheLactic Acid Bacteria. Vol 1: The Lactic Acid Bacteria in Health and Disease: London, UK: Elsevier Applied Science, 199, 69-114.
  3. Reuter G. The Lactobacillus and Bifidobacterium  Microflora of the Human Intestine: Composition and Succession. Curr Issues Intest Microbiol 2001;2:43-53.
  4. Valeur N, Engel P, Carbajal N, et al. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract.  Appl Environ Microbiol  2004; 70: 1176-81.
  5. Christensen HR, Frokiaer H, Pestka JJ . Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol  2002;168: 171-178
  6. Smits HH et al.  Selective Probiotic Bacteria Induced IL-10 Producing Regulatory T-cells invitro by Modulating Dendritic Cell Function Through Dendritic cell-specific Intercellular Adhesion Molecule 3-Grabbingtnoninterin.  J Allergy Clin Immunol 2005; 115: 1260-1261
  7. Pasare C, Medzhitov R. Toll Pathway Dependent Blockade of CD4+CD 25+ T Cell Mediated Suppression by Dendritic Cells. Science  2003; 1033-1036
  8. Casas IA, Dobogosz. Validation of the probiotic concept. Nutrafoods 2002; 12:247-285
  9. Bernard WV, Sebastian M, Hemming Bruce.  Salmonella antimicrobial activity of selected strains of enterolactobacillus species isolated from the gastrointestinal tract of the horse. Journal of Equine Veterinary Science 2011; 1-4
  10. Talarico TL and Dobrogosz. Chemical characterization of an antimicrobial substance produced by Lactobacillus reuteri.  Antimicrob Agents Chemother 1989; 33:674-679
  11. Weese JS. Microbologic evaluation of commercial probiotics. J Am Vet Med Assoc 2002;220: 794-797
  12. Shornikova AV, Casas IA, Mykkanen H et al.  Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritits. Pediatr Infect Dis J 1997; 16: 1103-1107
  13. Ruiz-Palacios G, Guerrero ML, Hilty M. Feeding of a probiotic for the prevention of community acquired diarrhea in young mexican children.  Pediatr. Res. (1996)39,184a abstract 1089
  14. Yuyama Y, Yusa S, Takai S. Evaluation of a host-specific lactobacillus probiotic in neonatal foals. Int J of App Res .
  15. Weese JS, Anderson MEC, Lowe A et al. Screening of the equine intestinal microflora for potential pobiotic organisms. Equine Vet J 2004; 4: 351-355
  16. Clancy R. Immunobiotics and the probiotic revolution. FEMS Immunol Med Micro 2003; 36: 9-12
  17. Desrochers A M,  Dolente A B,  Roy Marie-France et al.  Efficacy of Sacharomyces boulardi for Treatment of Horses With Acute Enterocolitis, J Am Vet Med Assoc 2005; 227: 954-959
  18. Butts  JP, Corthier G, delmee M. Saccharomyces boulardi for Clostridium-associated enteropathies in infants. J of Pediatr Gastro and Nutr  1993; 16: 419-425
  19. Gedek B R.   Adherence of E.Coli serogroup 0 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyce boulardii . Mycoces 1999: 42: 261-264
  20. Mcfarland L V, Surawicz C M, Greenberg RN  et al. A randomized placebo controlled trial of Saccharomyces  boulardii in Combination with Standard Antibiotics for Clostridium difficile Disease. JAMA  1994; 271: 1913-916
  21. Castagiuolo I, Riegler M F, Valenick L et al. Saccharomyces boulardii Protease Inibits The Effects of Clostridiium difficile  Toxins A and B in Human Colonic mucosa. Infect and Immun 1999; 67: 302-307
  22. Surawicz C M, Elmer GW, Speelman P et al. Prevention of Antibiotic -Associated Diarrhea by Saccharomyces boulardii:  A Prospective Study . Gastroenterology 1989;96:981-988
  23. McFarland LV, Surawicz CM, Greenberg RN et al. Prevention of Beta Lactam Associated Diarrhea by Saccharomyces boulardii Compared with Placebo. Am J of Gastro 1995; 90:439-442
  24. Kimmey MB, Elmer GW, Surawicz CM  et al. Prevention of Further Recurrence of Clostridium difficile Colitis with Saccharomyces boulardii . Digest Dis and Sci 1990; 35:897-901
  25. Bleichner G, Blehaut H, Mentec H et al. Saccharomyces boulardii prevents diarrhea in critically ill tube- fed patients . Intens Care Med 1997; 23: 517-523
  26. Casas IA, Dobogosz. Validation of the probiotic concept. Nutrafoods 2002; 12:247-285